“Our market penetration and revenue trajectory, which are driven by both strong organic growth and meaningful contributions from our recent acquisitions, continue to expand significantly. This continued growth is achieved all while we remain focused on further advancing our already unrivaled portfolio of genomic capabilities in oncology,” continued Sharma.
▪ Response Genetics’ Los Angeles clinical lab and facility will allow Cancer Genetics to expand its national sales and service footprint and serve a broader customer base while adding immediate revenue from both clinical and biopharma customers
▪ The transaction is expected to add an additional $10 to $12 million in revenue to CGI over the next year and is expected to close in early October
CGI will report financial results for the second quarter ended June 30, 2015 before the market open on Tuesday, August 11, 2015. The company will also hold a live investor conference call and webcast at 8:30am Eastern.
The presentation will take place on Monday, August 3rd at 10:15am (Mountain Time) at the Cancer Genomics Consortium and the Cytogenomics Array Group Meeting (CGC-CAGdb) in Denver, Colorado.
“Our team and many of our customers are very enthusiastic about Dr. Shaknovich joining CGI,” said Panna Sharma. “Her expertise at the vanguard of genomic research and clinical translation makes her uniquely suited to help CGI fulfill our mission and help further integrate our clinical and research efforts.”
The companies have entered into an agreement to offer biotech and pharmaceutical clients access to ICON Laboratory Services’ global central laboratory experience combined with Cancer Genetic’s expertise in oncology testing and genomic assay development.
“CGI has built deep expertise in CLL diagnosis, prognosis and theranosis through our work with both the clinical and biopharma community. This recent award is a testament to our team and our ability to provide actionable biomarker information that helps our biopharma partners,” said Panna Sharma, President and CEO of Cancer Genetics. “CLL is an […]
RUTHERFORD, N.J., June 1, 2015 — Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, today announced that Panna Sharma, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference. The presentation will take place at the Grand Hyatt New York on Thursday, June […]
RUTHERFORD, N.J., May 29, 2015 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today the presentation of results from a research collaboration with Memorial Sloan Kettering Cancer Center at the 2015 American Society of Clinical Oncology Annual Meeting, taking place at the McCormick Place Convention Center […]
RUTHERFORD, N.J. & HYDERABAD, INDIA, May 26, 2015 – Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or the “Company”) announced today that it was selected by Japanese regenerative medicine company, ReproCELL, Inc., to provide next-generation sequencing (NGS) based services and molecular information to enhance ReproCELL’s translational medicine initiatives. Under the terms of the agreement, CGI will […]
RUTHERFORD, N.J., and HYDERABAD, INDIA, May 22, 2015 — Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today the appointment of Mandar Kulkarni, PhD. as Chief Technology Officer (CTO) of Cancer Genetics, India, based in Hyderabad. In his role, Kulkarni will lead efforts to expand CG India’s technology […]
RUTHERFORD, N.J., May 12, 2015, Cancer Genetics, Inc. (Nasdaq: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the first quarter ended March 31, 2015.
RUTHERFORD, N.J., May 6, 2015 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it has entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center in Tampa, Florida. The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, […]
RUTHERFORD, NJ – May 5, 2015 – Cancer Genetics, Inc. (NasdaqCM: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2015 before the market opens on Tuesday, May 12, 2015. The company will hold a live investor conference call and webcast […]
Focus::Myeloid™ will help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently living with myeloid malignancies Over 100 clinical studies are being conducted by biotechnology and pharmaceutical companies for compounds targeting myeloid cancers that can potentially benefit from CGI’s Focus::Myeloid™ and improvements to enrollment, stratification and […]
Cancer Genetics India (CG India) has launched a Next-Generation Sequencing (NGS) based panel targeting the five most common solid tumors: breast, colorectal, lung, skin, and ovarian cancer for the Indian and broader Asian markets. The NGS-based panel provides a comprehensive genomic assessment of cancer mutations, with dramatically increased sensitivity compared to other testing methodologies, and can be applied to over 370,000 patients annually in India alone.
Cancer Genetics Inc announces NYS licensure for FHACT®, which will allow the company to market the test in New York State
CGI’s full range of oncology focused testing services will be available to an additional 19 million individuals in the US RUTHERFORD, NJ (April 01, 2015): Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, today announced that it has executed an agreement with America’s Choice Provider Network® (ACPN®), an independent national […]
Collaborations with Keck School of Medicine of USC, University of Alabama School of Medicine, and Westchester Medical Center at New York Medical College provide insight into the diagnosis and management of challenging cancers. The collaborations leverage the power of CGI’s unique, proprietary genomic panels, including MatBA® for diffuse large B-cell lymphoma (DLBCL), which is the […]
Fourth Quarter Revenues up 118 Percent Year over Year to $4 million Full-Year 2014 Revenue Increase up 54 Percent over 2013 to $10.2 Million Cancer Genetics to Host Conference Call Today, Thursday March 12th at 8:30 am Eastern Time / 5:30 am Pacific Time RUTHERFORD, N.J., March 12, 2015 – Cancer Genetics, Inc. (Nasdaq: CGIX), […]